|
26 Apr 2022 |
Update on Regulatory Submission for Aducanumab in the European Union
|
|
26 Apr 2022 |
Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
|
|
24 Apr 2022 |
Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
|
|
24 Apr 2022 |
New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance
|
|
21 Apr 2022 |
Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1
|
|
21 Apr 2022 |
Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
|
|
20 Apr 2022 |
VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders
|
|
20 Apr 2022 |
Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss
|
|
20 Apr 2022 |
Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta
|
|
20 Apr 2022 |
Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine
|
|
20 Apr 2022 |
Sanyou Bio congratulates Dragon Boat Pharmaceutical on the approval of clinical trials of anti-CLDN18.2 antibody drug BC008
|
|
20 Apr 2022 |
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
|
|
20 Apr 2022 |
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
|
|
20 Apr 2022 |
SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma
|
|
20 Apr 2022 |
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its RSV Vaccine Candidate in Older Adults
|
|
20 Apr 2022 |
SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
|
|
20 Apr 2022 |
BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications
|
|
20 Apr 2022 |
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
|
|
19 Apr 2022 |
Enhertu granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
|
|
19 Apr 2022 |
Amgen announces positive top-line results from phase 3 study of ABP 654, biosimilar candidate to Stelara (ustekinumab)
|
